Characteristics | n | % |
---|---|---|
Demographics | ||
Age, yrs, mean (SD) | 39.41 (15.48) | |
Sex: male/female, n | 1420/9868 | |
Index diagnosis yr | ||
2001–2004 | 4949 | 43.84 |
2005–2008 | 3622 | 32.09 |
2009–2012 | 2717 | 24.07 |
Comorbidity, 12 mos before index date | ||
Cerebrovascular disease | 535 | 4.74 |
Ischemic heart disease | 724 | 6.41 |
Diabetes mellitus | 679 | 6.02 |
Dyslipidemia | 1054 | 9.34 |
Renal dysfunction | 831 | 7.36 |
SLE severity index, 6 mos after cohort entry date | ||
Mild | 4109 | 36.40 |
Moderate | 3881 | 34.38 |
Severe | 3298 | 29.22 |
SLE medication, 12 mos after cohort entry date | ||
Glucocorticoid | 10,415 | 92.27 |
Injectable form | 4568 | 40.47 |
Other SLE medications | ||
NSAID | 8954 | 79.32 |
Hydroxychloroquine | 8998 | 79.71 |
Azathioprine | 3534 | 31.31 |
Cyclophosphamide | 1707 | 15.12 |
Mycophenolate mofetil | 221 | 1.96 |
Methotrexate | 591 | 5.24 |
Leflunomide | 35 | 0.31 |
Chlorambucil | 22 | 0.19 |
Rituximab | 3 | 0.03 |
Average daily prednisolone-equivalent dose, mg, first 3 mos | ||
Mean (SD) | 56.73 (447.66) | |
Median | 15.38 |
SLE: systemic lupus erythematosus; NSAID: nonsteroidal antiinflammatory drug.